EN DE
Watch Caregen Co.Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Caregen Co.Ltd (214370) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Caregen Co.Ltd stock KRW 5,414, price KRW 28,050, that is 80.7% below the price, quality 71 out of 100. Rating: strongly overvalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7214370009

CC Caregen Co.Ltd logo Thin data Nov 20, 2026

Caregen Co.Ltd

214370 · KQ

Far too expensive (fair value 81% below the price) and falling price, but solid company: meets 1 of 3 rules.

Follow free in the weekly email
Quality 71/100 
Highly profitable · 39.6% net margin (TTM) 
Generates free cash flow 
Revenue last quarter +34% vs. a year ago. 
Mixed Growth (revenue 5y +3.8 %/yr in KRW) 
2.1% dividend yield · Safety not assessed
Mixed vs. peers (6/11) 
Wide moat 82/100 · thin data
Fair value 5,414 KRW · Strongly overvalued 
Falling price (downtrend) 
Thin data 
Extreme value
Watch Caregen Co.Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

149,635 KRW 9,606 KRW Fair Value 5,414 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 20, 2026.

How to read this chart

60‑month range 9,606 KRW – 149,635 KRW · fair‑value band 3,672 KRW – 7,690 KRW · the 28,050 KRW price screens above the 5,414 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 20, 2026.

Follow Caregen Co.Ltd in your weekly email

Every Wednesday you see whether Caregen Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands.

Show moreShow less

It also provides medical devices under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG Styler 600 names.

The company's products are used in anti-aging, anti-pigmentation, anti-hair loss, anti-inflammation, and other skin troubles, as well as blood sugar control, baby skin care, and acute muscle pain applications.

In addition, its products in pipeline include pharmaceuticals in the areas of wet and dry macular degeneration, diabetic retinopathy, cataract, hyperhidrosis, pain relief, obesity, psoriasis, scar, arthritis, rhinitis, anti-virus, and Covid-19 treatment; and medical devices for face beauty treatment, scalp and hair improvement, body care, arthritis, and new face beauty treatment.

Further, the company is developing cosmeceutical produts for anti-wrinkle, whitening, sun block, atopic dermatitis care, particulate matter inhibition, double chin removal, dark circle care, reduction of cellulite, sebum secretion control, and pore tightening applications; and food supplements in the areas of hangover cure, cholesterol control, and body fat lipolysis.

Caregen Co., Ltd. was founded in 2001 and is based in Anyang-si, South Korea.

Stock analysis

Caregen Co.Ltd (214370) currently trades at 28,050 KRW, while our model-based Fair Value estimate is 5,414 KRW, 81% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Dividend Discount group reads highest at a median of 8,286 KRW per share, and 0 of the 25 models we run sit above the 28,050 KRW price.

Bear case: the Asset-Based group reads lowest at 1,317 KRW, and 25 of the 25 models stay below the price. Data coverage for this calculation is low.

Scenario range: 3,672 KRW (bear) to 7,690 KRW (bull), the price of 28,050 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Caregen Co.Ltd reported revenue of 72.8B KRW in FY2025 versus 59.1B KRW in FY2021, a compound +5.4%/yr. Reported net income was 20.1B KRW in FY2025, compounding −5.6%/yr from FY2021.

Key figures

Market cap 1.4T KRW (≈ $1.0B) Small · P/S ratio 20.2 · Dividend yield 2.1% · Net margin 39.6% · Return on equity 1,456% · Return on assets (EBIT) 13.3% (5-year average) · Operating margin 46.3% · Revenue (TTM) 65.0B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 82 out of 100 (low confidence).

What moves the price

The share trades about 81% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −22% fair-value upside, at −81%, 214370 screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (1,317 KRW to 19,099 KRW). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear 3,672 KRW Fair Value 5,414 KRW Bull 7,690 KRW
Price 28,050 KRW · Downside -80.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 2,861 KRW 3,917 KRW 5,302 KRW 79
Growth DCF 2,914 KRW 3,875 KRW 5,077 KRW 77
Residual Income 3,672 KRW 3,991 KRW 4,534 KRW 76
All 25 models by family
DCF Models
FCF DCF 2,861 KRW 3,917 KRW 5,302 KRW 79
Owner Earnings 1,678 KRW 2,268 KRW 3,042 KRW 75
5Y Revenue Exit 3,015 KRW 4,514 KRW 6,366 KRW 70
5Y EBITDA Exit 4,136 KRW 6,519 KRW 9,201 KRW 72
5Y P/E Exit 4,840 KRW 7,778 KRW 10,735 KRW 68
10Y Revenue Exit 2,845 KRW 4,126 KRW 5,722 KRW 65
10Y EBITDA Exit 3,592 KRW 5,414 KRW 7,690 KRW 66
10Y P/E Exit 4,010 KRW 6,223 KRW 8,754 KRW 61
Earnings-Based
Graham-Dodd 2,797 KRW 6,836 KRW 8,844 KRW 65
PEG = 1.0 3,555 KRW 5,078 KRW 6,602 KRW 57
EPV 2,283 KRW 2,593 KRW 2,855 KRW 70
Dividend Discount
Gordon GGM 5,280 KRW 8,932 KRW 13,027 KRW 67
DDM Multi-Stage 5,280 KRW 7,640 KRW 9,994 KRW 67
Multiples
P/E Multiple 6,786 KRW 9,048 KRW 11,310 KRW 63
P/S Multiple 3,911 KRW 5,214 KRW 6,518 KRW 58
P/B Multiple 14,324 KRW 19,099 KRW 23,874 KRW 55
EV/EBIT 5,503 KRW 7,277 KRW 9,052 KRW 63
EV/EBITDA 5,642 KRW 7,463 KRW 9,283 KRW 64
EV/Revenue 3,310 KRW 4,651 KRW 5,992 KRW 51
Asset-Based
NCAV (Graham) 868.98 KRW 1,317 KRW 1,646 KRW 52
Growth DCF
Growth DCF 2,914 KRW 3,875 KRW 5,077 KRW 77
Rev-Margin DCF 3,015 KRW 4,540 KRW 6,189 KRW 70
Economic Profit
Residual Income 3,672 KRW 3,991 KRW 4,534 KRW 76
ROIC Compounder 2,283 KRW 2,593 KRW 2,855 KRW 70
Growth Earnings
Growth-Adj P/E 5,177 KRW 7,396 KRW 9,615 KRW 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 71/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 51
How much profit the company makes from its sales and capital
Quality Growth 27
Are margins and returns getting better?
Cashflow 65
Do the profits arrive as real cash?
Financial strength 83
Debt, balance sheet and risk of trouble
Investment 91
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 1
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 84
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 70/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−11.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.8%
Start year 2020 (pandemic). Over 10 years: +7.2% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.2%
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−30.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−32.0%
Dividend (yield on the price)2.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−32.0% vs −15.3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.53% → 28%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 15.0%/yr over ~7Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+42.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +39.1% a year for the price.

214370 screens overvalued: fair value 81% below the price. Compare with ST Pharm Co →

Compare Caregen Co.Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 57 stocks

Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 71 · Top 25%
Fair Value upside −80.7% · Bottom 25%
Profitability
Return on assets 8.7% · Top 25%
Net margin (12 months) 39.6% · Top 25%
Operating margin (12 months) 46.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 34.2% · Above median
Dividend yield (12 months) 2.1% · Above median

Valuation Multiplesvs Pharmaceuticals median · lower = cheaper

P/B 6.45× · Priciest 25%
P/S (12 months) 21.09× · Priciest 25%
Price / free cash flow (fiscal year) 100.3× · Priciest 25%
EV/EBITDA 41.4× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 9
FUTURE (revenue growth)100 · sector 68
PAST (return on equity)0 · sector 23
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)41 · sector 27

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Huons Global Co 084110 19,530 KRW 47,019 KRW +141% vs 214370
VIKRAMTH VIKRAMTH ₹325.05 ₹352.17 +8% vs 214370
DongKook Pharmaceutical Co 086450 26,700 KRW 28,372 KRW +6% vs 214370
ST Pharm Co 237690 75,000 KRW 61,182 KRW −18% vs 214370
Vivozon Pharmaceutical Co 082800 2,800 KRW 2,179 KRW −22% vs 214370
Oscotec Inc 039200 32,400 KRW 21,262 KRW −34% vs 214370
NatureCell Co 007390 21,300 KRW 11,176 KRW −48% vs 214370
Mezzion Pharma Co 140410 61,700 KRW 31,450 KRW −49% vs 214370
BINEX Co 053030 7,010 KRW 1,844 KRW −74% vs 214370
SHUKRAPHAR SHUKRAPHAR ₹82.22 ₹9.14 −89% vs 214370

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Caregen Co.Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Caregen Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/214370

Frequently asked questions

Is Caregen Co.Ltd (214370) overvalued or undervalued?
As of Nov 20, 2026, our model estimates a fair value of 5,414 KRW versus a price of 28,050 KRW, about 81% lower (overvalued).
What is the fair value of 214370?
Our model-based fair value for Caregen Co.Ltd is 5,414 KRW (as of Nov 20, 2026), built from audited fundamentals. The current price: 28,050 KRW.
What is the quality score of 214370?
Caregen Co.Ltd has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Caregen Co.Ltd (214370)?
We do not set a price target; the yardstick is the fair value of 5,414 KRW (as of Nov 20, 2026) from 25 valuation models. Cautious scenario 3,672 KRW, optimistic scenario 7,690 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Caregen Co.Ltd stock forecast for 2026?
Our models put fair value at 5,414 KRW, about 81% lower versus a price of 28,050 KRW (overvalued). Cautious scenario 3,672 KRW, optimistic scenario 7,690 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Caregen Co.Ltd (214370)?
Caregen Co.Ltd reported trailing-twelve-month revenue of about 65.0B KRW (latest available figure, as of Nov 20, 2026).
Does Caregen Co.Ltd pay a dividend?
Caregen Co.Ltd currently shows a dividend yield of 2.05% relative to its recent price (as of Nov 20, 2026).
How much is the dividend of Caregen Co.Ltd (214370)?
Caregen Co.Ltd has a dividend yield of 2.1%. A dividend has been paid every year since at least 2015. Our assessment: Safety not assessed. Payout ratio and cash coverage are not available, so we do not judge how safe this dividend is.
What growth is priced into Caregen Co.Ltd (214370)?
For today's price to be fair in a discounted-cash-flow model, Caregen Co.Ltd would have to grow free cash flow by 42.0 % per year for five years (discount rate 10.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 3.8 % per year. As of Nov 20, 2026.
What discount rate (WACC) does the fair value of 214370 use?
Our models discount Caregen Co.Ltd at 10.2 %: a base by market capitalisation (small), damped by beta 0.18, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Caregen Co.Ltd that is +42.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.2 %) and the same formula as our fair value.
How much growth has Caregen Co.Ltd (214370) delivered so far?
Over the past 5 years revenue at Caregen Co.Ltd grew 3.8 % a year. The price currently implies free-cash-flow growth of +42.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Caregen Co.Ltd (214370) growing?
The median revenue growth in the sector is +7.5 % a year. That is the yardstick for the growth priced into Caregen Co.Ltd (+42.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Caregen Co.Ltd (214370)?
The free-cash-flow yield on the price is 1.00 %: that much free cash flow Caregen Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Caregen Co.Ltd (214370)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Caregen Co.Ltd it is 5,414 KRW per share (as of Nov 20, 2026), against a price of 28,050 KRW. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Caregen Co.Ltd stock overvalued or undervalued in 2026?
As of Nov 20, 2026, 214370 trades above its calculated fair value: price 28,050 KRW, fair value 5,414 KRW, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 214370?
No. The price is what the market pays today (28,050 KRW); the fair value is what the company's own numbers justify (5,414 KRW). For Caregen Co.Ltd the two are 22,636 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Caregen Co.Ltd worth?
The market values Caregen Co.Ltd at about 1.4T KRW (market capitalisation, as of Nov 20, 2026). Per share that is 28,050 KRW; our models calculate a fair value of 5,414 KRW per share.
What do the bullish and bearish scenarios say about 214370?
Our models span a range for Caregen Co.Ltd: cautious scenario 3,672 KRW, base 5,414 KRW, optimistic 7,690 KRW per share (as of Nov 20, 2026, price 28,050 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 214370 from its 52-week high?
Caregen Co.Ltd trades at 28,050 KRW, about 81% below its 52-week high of 149,635 KRW and 5% above the low of 26,600 KRW (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of 5,414 KRW is for.
Which stocks are comparable to Caregen Co.Ltd?
From the same area (Healthcare) we also value ST Pharm Co, Mezzion Pharma Co, NatureCell Co, Oscotec Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Caregen Co.Ltd stock attractive at the current price?
The data as of Nov 20, 2026: price 28,050 KRW, calculated fair value 5,414 KRW (−81%), Quality Score 71/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 214370 calculated?
We run Caregen Co.Ltd through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 5,414 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 11.0% above its aggregate fair value. Caregen Co.Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Caregen Co.Ltd (214370)?
The closing price on Nov 19, 2026 was 28,050 KRW. Our model-based fair value is 5,414 KRW, about 81% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Caregen Co.Ltd right now?
The price sits above even our optimistic bull case (7,690 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (71/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (3,672 KRW to 7,690 KRW) leaves room in how you read the outcome.

Key figures of Caregen Co.Ltd

How large is the market capitalisation of Caregen Co.Ltd (214370)?
The market capitalisation of Caregen Co.Ltd is 1.4T KRW (≈ $1.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Caregen Co.Ltd (214370)?
The price-to-sales ratio of Caregen Co.Ltd is 20.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Caregen Co.Ltd (214370)?
The dividend yield of Caregen Co.Ltd is 2.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Caregen Co.Ltd (214370)?
The net margin of Caregen Co.Ltd is 39.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Caregen Co.Ltd (214370)?
The return on equity (ROE) of Caregen Co.Ltd is 1,456% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Caregen Co.Ltd (214370)?
On an EBIT basis the return on assets of Caregen Co.Ltd is 13.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Caregen Co.Ltd (214370)?
The operating margin of Caregen Co.Ltd is 46.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Caregen Co.Ltd (214370)?
Revenue at Caregen Co.Ltd is growing 34.2% versus a year earlier (3y avg +1.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Caregen Co.Ltd (214370)?
Earnings per share at Caregen Co.Ltd are down 4.4% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch Caregen Co.Ltd in the live analysis

One click puts Caregen Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.